Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression

Trial Profile

Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 May 2018

At a glance

  • Drugs MP 101 Mediti Pharma (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Mediti Pharma
  • Most Recent Events

    • 23 Mar 2018 Planned number of patients changed from 200 to 100.
    • 23 Mar 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2021.
    • 23 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top